Recently, researchers also found that bromodomain-containing protein BRD9, one subunit of SWI/SNF complex, could interact with AR and CCCTC-binding factor (CTCF) to control AR-dependent gene expressions, highlighting the translational significance of nontoxic BRD9 inhibitors in PRAD treatment [28]. Here, CTCF is linked to prostate adenocarcinoma.